glp-1 agonist consultation process and Anesthesia: Considerations and Cautions for CRNAs GLP-1 receptor agonists and next-generation
Description
Diabetes 54 , 146151 (2005)
doi: 10.1159/000517849
March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD
[DOI] [PMC free article] [PubMed] [Google Scholar] 66
PL: Writing review & editing, Funding acquisition, Supervision
